Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Talidox, a liposomal formulation of Doxorubicin, is currently tested in a clinical trial Phase I in cancer patients in Swiss hospitals.

Cooperation possibilities

International and national research collaborations have been established (e.g. University of Bern, University of Honolulu) and could be further expanded in areas such as cancer, neurodegenerative and auto-inflammatory diseases, paving the way for the development of novel nano-carrier based drugs.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2000
  • Number of employees in Switzerland
    20-49
Key business